Core Viewpoint - Antu Biology's stock performance shows a slight increase, with a trading volume of 1.11 billion yuan and a net financing buy of 640,600 yuan on January 6, indicating low financing levels compared to historical data [1] Financing Summary - On January 6, Antu Biology had a financing buy of 13.26 million yuan and a financing repayment of 12.62 million yuan, resulting in a net financing buy of 640,600 yuan [1] - The total financing and securities lending balance for Antu Biology reached 463 million yuan, with the financing balance at 459 million yuan, accounting for 2.21% of the circulating market value, which is below the 10th percentile of the past year [1] - The securities lending data shows a repayment of 700 shares and a sale of 600 shares, with a total sale amount of 21,800 yuan, and a securities lending balance of 3.99 million yuan, also below the 50th percentile of the past year [1] Company Performance Summary - As of September 30, Antu Biology had 34,000 shareholders, a decrease of 0.58% from the previous period, with an average of 16,816 circulating shares per shareholder, an increase of 0.58% [2] - For the period from January to September 2025, Antu Biology reported a revenue of 3.13 billion yuan, a year-on-year decrease of 7.48%, and a net profit attributable to shareholders of 860 million yuan, down 10.11% year-on-year [2] - Since its A-share listing, Antu Biology has distributed a total of 4.05 billion yuan in dividends, with 1.79 billion yuan distributed over the past three years [2] Shareholder Structure Summary - As of September 30, 2025, the top ten circulating shareholders of Antu Biology include Zhonggeng Value Pioneer Stock, holding 7.84 million shares, a decrease of 1.42 million shares from the previous period [2] - Hong Kong Central Clearing Limited is the fourth largest shareholder with 7.15 million shares, an increase of 421,430 shares [2] - Other notable changes include a decrease in holdings by Huabao Zhongzheng Medical ETF and an increase in holdings by Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A [2]

1月5日，热景生物盘中上涨2.07%，截至10:11，报165.35元/股，成交8409.05万元，换手率0.56%，总市 值153.29亿元。 资金流向方面，主力资金净流出756.27万元，特大单买入485.17万元，占比5.77%，卖出851.55万元，占 比10.13%；大单买入1485.18万元，占比17.66%，卖出1875.07万元，占比22.30%。 热景生物今年以来股价涨2.07%，近5个交易日跌0.99%，近20日跌7.89%，近60日涨1.87%。 资料显示，北京热景生物技术股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业基地庆 丰西路55号院7号楼1-5层，成立日期2005年6月23日，上市日期2019年9月30日，公司主营业务涉及研 发、生产和销售体外诊断试剂及仪器。主营业务收入构成为：检测试剂70.87%，检测仪器19.79%，其 他8.17%，生物原料1.17%。 热景生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：食品检测、创新药、猴 痘概念、肝炎治疗、阿尔茨海默等。 截至9月30日，热景生物股东户数7833.00，较上期增加12.90%；人均流通股 ...

责任编辑：小浪快报 资料显示，郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号，成 立日期1999年9月15日，上市日期2016年9月1日，公司主营业务涉及体外诊断试剂及仪器的研发、生产 和销售。主营业务收入构成为：试剂86.63%，仪器10.99%，其他1.40%，维保收入0.98%。 截至9月30日，安图生物股东户数3.40万，较上期减少0.58%；人均流通股16816股，较上期增加0.58%。 2025年1月-9月，安图生物实现营业收入31.27亿元，同比减少7.48%；归母净利润8.60亿元，同比减少 10.11%。 分红方面，安图生物A股上市后累计派现40.46亿元。近三年，累计派现17.94亿元。 机构持仓方面，截止2025年9月30日，安图生物十大流通股东中，中庚价值先锋股票（012930）位居第 三大流通股东，持股783.61万股，相比上期减少141.73万股。香港中央结算有限公司位居第四大流通股 东，持股714.85万股，相比上期增加421.43万股。华宝中证医疗ETF（512170）位居第五大流通股东， 持股483.37万股，相比上期减少90.91万股。大成睿 ...

点击免费限量礼盒 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 二轮问询中，北交所请发行人逐一说明发行人及杨致国控制的7家企业获取重叠客户及供应商的具体途径、合作历史、 是否同时进入客户及供应商体系，存在重叠客户及供应商的合理性。说明报告期内发行人及杨致国控制的7家企业的收 入、利润、向重叠客户的销售金额及占比情况、向重叠供应商采购金额及占比情况。并说明发行人及杨致国控制的7家 企业是否存在配套采购销售、共同采购销售情形，与重叠客户及供应商合同签订的时间及人员是否存在重叠，是否存在 互相引荐、协助获取订单的情形，是否存在业务或者市场切割约定。同时，分析说明向重叠客户及供应商购销价格的公 允性，价格差异原因及合理性，是否存在让渡商业机会的情形。 北交所还要求康华股份披露公司及其子公司与杨致国控制的7家企业报告期内的交易或资金往来情况，发行人未来有无 收购前述相关企业的计划。结合实际控制人与关系密切的家庭成员及其直接或间接控制的企业与杨致国、杨永盛及其关 联方、关联企业的资金流水情况，说明是否存在利益输送情形。 | 版 权 ： 本 文 部 分 ...

Group 1 - The core point of the news is that 热景生物 (Hotgen Biotech) experienced a decline of 5.13% in its stock price, reaching 163.17 CNY per share, with a trading volume of 1.18 billion CNY and a market capitalization of 15.127 billion CNY [1] - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition is as follows: testing reagents 70.87%, testing instruments 19.79%, others 8.17%, and biological raw materials 1.17% [1] Group 2 - 中航优选领航混合发起A (CASC Optimal Selection Mixed Fund A) has increased its holdings in Hotgen Biotech by 53,100 shares in the third quarter, bringing the total to 290,100 shares, which constitutes 11.14% of the fund's net value, making it the fourth-largest holding [2] - The fund has reported a floating loss of approximately 2.5616 million CNY as of the latest data [2] - The fund manager, 王森 (Wang Sen), has been in charge for 2 years and 55 days, with the fund's total asset size at 2.85 billion CNY. The best return during his tenure is 132.1%, while the worst return is -0.6% [3]

Core Viewpoint - The stock of Beijing Hotgen Biotech Co., Ltd. increased by 5.32% on November 10, reaching a price of 143.50 yuan per share, with a trading volume of 276 million yuan and a turnover rate of 2.11%, resulting in a total market capitalization of 13.304 billion yuan [1]. Company Overview - Beijing Hotgen Biotech Co., Ltd. was established on June 23, 2005, and went public on September 30, 2019. The company is located in the Daxing District of Beijing and specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments [1]. - The revenue composition of the company includes: 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1]. Fund Holdings - According to data, one fund under Huaxia Fund has a significant holding in Hotgen Biotech. The Huaxia SSE STAR 200 ETF (588820) increased its holdings by 28,000 shares in the third quarter, bringing the total to 29,600 shares, which accounts for 1.06% of the fund's net value, making it the tenth largest holding [2]. - The Huaxia SSE STAR 200 ETF (588820) was established on December 23, 2024, with a latest scale of 476 million yuan. Year-to-date, it has achieved a return of 53.55%, ranking 500 out of 4217 in its category, and a cumulative return of 52.86% since inception [2]. Fund Manager Information - The fund manager of the Huaxia SSE STAR 200 ETF (588820) is Hualong. As of the report date, Hualong has been in the position for 3 years and 82 days, managing total assets of 35.957 billion yuan. The best fund return during this period was 107.73%, while the worst was -15.08% [3].

Core Viewpoint - The stock of Hotgen Biotech experienced a decline of 2.01% on November 7, with a current price of 136.99 CNY per share and a total market capitalization of 12.7 billion CNY. The company has seen a significant increase in stock price of 121.52% year-to-date, but has faced recent declines over various time frames [1][2]. Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million CNY, representing a year-on-year decrease of 19.80%. The net profit attributable to shareholders was -109 million CNY, a significant decline of 168.12% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 440 million CNY, with 17.34 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Hotgen Biotech increased by 12.90% to 7,833, while the average circulating shares per person decreased by 11.43% to 11,835 shares [2]. - The top ten circulating shareholders include various funds, with notable changes in holdings: Huatai-PineBridge Innovation Medicine Mixed Fund reduced its holdings by 12.53%, while ICBC Frontier Medical Stock A increased its holdings by 50.00% [3]. Market Activity - The stock has been active on the trading board, appearing five times this year, with the most recent net purchase on July 4 amounting to 47.83 million CNY, accounting for 25.69% of total trading volume [1]. - The stock has experienced a decline of 14.38% over the last five trading days, 15.44% over the last 20 days, and 42.20% over the last 60 days [1]. Business Overview - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition includes 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics, with involvement in concepts such as Alzheimer's, innovative drugs, antigen testing, and monkeypox [2].

Core Insights - The stock price of Hotgen Biotech increased by 2.09% on October 31, reaching 150.27 CNY per share, with a total market capitalization of 13.93 billion CNY [1] - Year-to-date, the stock has risen by 143%, but it has seen a decline of 6.35% in the last five trading days, 13.46% in the last 20 days, and 22.94% in the last 60 days [1] - The company has reported a significant decrease in revenue and net profit for the first nine months of 2025, with revenue of 310 million CNY, down 19.80% year-on-year, and a net loss of 109 million CNY, a decrease of 168.12% [2] Financial Performance - Hotgen Biotech's main business revenue composition includes 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from other sources, and 1.17% from biological raw materials [1] - Cumulative cash dividends since the company's A-share listing amount to 440 million CNY, with 17.34 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average circulating shares per person decreased by 11.43% to 11,835 shares [2] - The top ten circulating shareholders include various funds, with notable changes in holdings among them, such as a decrease in shares held by Huatai-PineBridge Innovation Medicine Mixed A and an increase by ICBC Frontier Medical Stock A [3]

Core Viewpoint - Antu Biology is a leading company in the in vitro diagnostics sector in China, with a comprehensive product range and strong market position, ranking second in revenue and third in net profit among industry peers in Q3 2025 [1][2]. Group 1: Business Performance - In Q3 2025, Antu Biology reported revenue of 3.127 billion yuan, ranking second among 39 companies in the industry, with the top company generating 3.428 billion yuan [2]. - The revenue composition includes 1.785 billion yuan from reagents (86.63%), 226 million yuan from instruments (10.99%), and 28.9 million yuan from other sources (1.40%) [2]. - The net profit for the same period was 873 million yuan, placing the company third in the industry, with the leading company achieving 1.588 billion yuan [2]. Group 2: Financial Ratios - As of Q3 2025, Antu Biology's debt-to-asset ratio was 24.57%, higher than the industry average of 18.29%, but down from 25.49% in the previous year [3]. - The gross profit margin stood at 64.83%, exceeding the industry average of 56.20%, although it slightly decreased from 65.86% year-on-year [3]. Group 3: Management and Shareholder Information - The chairman, Miao Yongjun, received a salary of 1.06 million yuan in both 2024 and 2023, indicating stability in compensation [4]. - As of September 30, 2025, the number of A-share shareholders decreased by 0.58% to 34,000, while the average number of shares held per shareholder increased by 0.58% to 16,800 [5]. Group 4: Market Outlook and Innovations - The company is actively expanding its overseas market presence, with overseas revenue reaching 157 million yuan in the first half of 2025, a year-on-year increase of 19.8% [5]. - Antu Biology plans to launch new products, including a liquid chromatography-tandem mass spectrometry series in 2025, and has made significant progress in the NGS sector through its subsidiary [6]. - The company is expected to see a gradual recovery in performance, with projected net profits of 1.108 billion yuan, 1.340 billion yuan, and 1.617 billion yuan for 2025, 2026, and 2027, respectively [6].

Core Insights - The company has reported a net loss of 109 million yuan for the first three quarters of the year, continuing a trend of losses for three consecutive years [1] - Despite the losses, the company's stock price has surged this year due to the popularity of innovative drugs, although several shareholders have significantly reduced their holdings in the past six months [1] Financial Performance - For the first three quarters, the company achieved an operating revenue of 310 million yuan, a year-on-year decrease of 19.8% [1] - The net profit attributable to shareholders was -109 million yuan, with a year-on-year loss increase of 168.12% [1] - The basic earnings per share were -1.23 yuan [1] Historical Financial Trends - Historical financial data indicates that from 2022 to 2024, both operating revenue and net profit have declined for three consecutive years [1] - Revenue has decreased year-on-year by 33.76% in 2022, 84.78% in 2023, and 6.74% in 2024 [1] - Net profit has also seen significant declines, with decreases of 56.78% in 2022, 97.1% in 2023, and a projected loss of 191 million yuan in 2024, marking the company's first annual loss since its listing [1] Company Overview - Founded in 2005, the company focuses on the biopharmaceutical sector, specializing in the research, development, production, and sales of in vitro diagnostic reagents and instruments [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in September 2019 [1] - The IVD (in vitro diagnostics) sector index has increased by 8.25% year-to-date [1]